(Q34430476)

2 August 2017

title

Current and future potential roles of the platinum drugs in the treatment of ovarian cancer (English)

1 reference

2 August 2017

1 reference

1 reference

M J Piccart

1

1 reference

2 August 2017

H Lamb

series ordinal

2

1 reference

2 August 2017

J B Vermorken

series ordinal

3

1 reference

2 August 2017

publication date

1 September 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

12

1 reference

2 August 2017

issue

9

1 reference

2 August 2017

page(s)

1195-1203

1 reference

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Chemotherapy for ovarian cancer--a consensus statement on standard practice.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Platinum alone for chemotherapy for ovarian cancer?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

ICON2 trial. UK consensus statement on standard practice for chemotherapy in ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Second-line treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Clinical perspectives on platinum resistance

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Comparative adverse effect profiles of platinum drugs.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Clinical pharmacokinetics and administration of established platinum drugs

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Carboplatin versus cisplatin in solid tumors: an analysis of the literature

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Preclinical perspectives on platinum resistance

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

p53 and chemosensitivity.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

New developments and approaches in the platinum arena

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Clinical development of platinum complexes in cancer therapy: an historical perspective and an update.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Oxaliplatin: a review of preclinical and clinical studies.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Successful treatment with nedaplatin in patients with ovarian cancer that recurred after platinum-containing chemotherapy: report of two cases

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012259625746

7 January 2021

Identifiers

DOI

10.1023/A:1012259625746

1 reference

2 August 2017

1 reference